Eisai Co., Ltd. (TYO: 4523)
Japan
· Delayed Price · Currency is JPY
5,479.00
-74.00 (-1.33%)
Oct 11, 2024, 3:15 PM JST
Eisai Revenue
Eisai had revenue of 189.03B JPY in the quarter ending June 30, 2024, a decrease of -4.01%. This brings the company's revenue in the last twelve months to 733.85B, down -3.07% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
733.85B
Revenue Growth
-3.07%
P/S Ratio
2.14
Revenue / Employee
66.31M
Employees
11,067
Market Cap
1,544.46B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEisai News
- 27 days ago - Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer - Seeking Alpha
- 27 days ago - KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma - Benzinga
- 4 weeks ago - Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges - Benzinga
- 4 weeks ago - Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment - CNBC
- 7 weeks ago - Biogen, Eisai new Alzheimer’s drug considered too costly in Britain - Seeking Alpha
- 7 weeks ago - Biogen/Eisai’s Alzheimer's drug wins marketing authorization in Great Britain - Seeking Alpha
- 7 weeks ago - UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug - Reuters
- 7 weeks ago - Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED - Seeking Alpha